STOCK TITAN

Diane M. Bryant Joins Haemonetics' Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

BOSTON, Aug. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has announced the election of Diane M. Bryant to its Board of Directors.

Bryant recently served as Chairman and Chief Executive Officer of NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health. She is the former Chief Operating Officer of Google Cloud and spent 32 years at Intel Corporation, where she held numerous leadership roles of increasing responsibility, including serving as Group President of the Data Center Group. Bryant was named one of Fortune's 50 Most Powerful Women in Business in 2015 and 2016. She also serves on the board of directors of Broadcom Inc. and the Chancellor's Board of Advisors at the University of California, Davis.

Bryant received a Bachelor of Science in electrical engineering from the University of California, Davis, and she attended the Stanford Graduate School of Business, completing the Executive Program.

"Diane brings to Haemonetics' Board more than three decades of executive leadership, directing the growth of prominent global technology organizations," said Ellen Zane, Chair of Haemonetics' Board of Directors. "As Haemonetics continues to extend its industry leadership, we look forward to leveraging Diane's extensive technology and healthcare experience and strategic counsel towards achieving the company's goals for long-term, transformational growth."

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:                                 


Olga Guyette, Sr. Director-Investor Relations & Treasury                 

David Trenk, Manager-Investor Relations

(781) 356-9763                                                                                   

(203) 733-4987

olga.guyette@haemonetics.com                                                         

david.trenk@haemonetics.com  

 

Media Contact:                             


Josh Gitelson, Director-Global Communications           


(781) 356-9776                     


josh.gitelson@haemonetics.com               


 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/diane-m-bryant-joins-haemonetics-board-of-directors-301894585.html

SOURCE Haemonetics Corporation

Haemonetics Corporation

NYSE:HAE

HAE Rankings

HAE Latest News

HAE Stock Data

4.74B
50.37M
0.76%
101.04%
4.01%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
BOSTON

About HAE

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right